Cargando…

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice

OBJECTIVES: Changes in treatment choice of therapy and size of treated population that can lead to under- or overestimate of payer’s budget are less likely to be reassured after reimbursement adoption of a new drug. The aim of this study was to evaluate the effects of febuxostat introduction and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Yueh-Lung, Lee, Chien-Te, Tain, You-Lin, Huang, Yaw-Bin, Chuang, Hung-Yi, Wen, Yen-Hsia, Huang, Shiou-Huei, Tsai, Chun-Yu, Hsu, Chien-Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709886/ https://www.ncbi.nlm.nih.gov/pubmed/31449565 http://dx.doi.org/10.1371/journal.pone.0221504

Ejemplares similares

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

Adherence to long-term use of renin-angiotensin II-aldosterone system inhibitors in children with chronic kidney disease
por: Hsu, Chien-Ning, et al.
Publicado: (2019)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Melatonin Therapy Prevents Programmed Hypertension and Nitric Oxide Deficiency in Offspring Exposed to Maternal Caloric Restriction
por: Tain, You-Lin, et al.
Publicado: (2014)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

The Stiff Joint: Comparative Evaluation of Monotherapy and Combination Therapy With Urate Lowering Agents in Managing Acute Gout
por: Okobi, Okelue E, et al.
Publicado: (2023)

Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database
por: Liu, Ching-Han, et al.
Publicado: (2022)

Factors associated with initiation and persistence of urate-lowering therapy
por: Dehlin, Mats, et al.
Publicado: (2017)

Review of Urate-Lowering Therapeutics: From the Past to the Future
por: Jenkins, Christopher, et al.
Publicado: (2022)

Trends in Antimicrobial Susceptibility of Escherichia coli Isolates in a Taiwanese Child Cohort with Urinary Tract Infections between 2004 and 2018
por: Chen, Hung-En, et al.
Publicado: (2020)

Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus
por: Chang, Hsin-Wen, et al.
Publicado: (2019)

Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study
por: Chen, Rong-Jane, et al.
Publicado: (2016)

Circulating microRNAs and vascular calcification in hemodialysis patients
por: Lee, Chien-Te, et al.
Publicado: (2019)

Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan
por: Huang, Shiou-Huei, et al.
Publicado: (2012)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
por: Chen, Hung-Jen, et al.
Publicado: (2020)

Acid suppressive agents and risk of Mycobacterium Tuberculosis: case–control study
por: Hsu, Wen-Hung, et al.
Publicado: (2014)

Changing trends in dialysis modalities utilization and mortality in children, adolescents and young adults with acute kidney injury, 2010–2017
por: Tain, You-Lin, et al.
Publicado: (2021)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function
por: Jeon, Hee Jung, et al.
Publicado: (2019)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
por: Sapankaew, Tunlanut, et al.
Publicado: (2022)

Incidence, Outcomes, and Risk Factors of Community-Acquired and Hospital-Acquired Acute Kidney Injury: A Retrospective Cohort Study
por: Hsu, Chien-Ning, et al.
Publicado: (2016)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD
por: Sun, Mingyao, et al.
Publicado: (2022)

Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes
por: Zhang, Bingqing, et al.
Publicado: (2019)

Maternal Melatonin Therapy Attenuates Methyl-Donor Diet-Induced Programmed Hypertension in Male Adult Rat Offspring
por: Tain, You-Lin, et al.
Publicado: (2018)

Long-Term Effects of Maternal Citrulline Supplementation on Renal Transcriptome Prevention of Nitric Oxide Depletion-Related Programmed Hypertension: The Impact of Gene-Nutrient Interactions
por: Tain, You-Lin, et al.
Publicado: (2014)

Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway
por: Wang, Jen-Chun, et al.
Publicado: (2023)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
por: te Kampe, Ritch, et al.
Publicado: (2022)

The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study
por: Hsu, Wei-Lung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fa337bdf153qkrhe0qg2hikfjt